Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells-Reference-Cited by-同舟云学术

Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells

Published:2015-05-12 Issue:9 Volume:137 Page:2234-2242
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Göckeritz Elisa¹²,Kerwien Susan¹,Baumann Michael¹,Wigger Marion¹,Vondey Verena¹²,Neumann Lars¹²,Landwehr Thomas¹,Wendtner Clemens M.¹,Klein Christian³,Liu Ningshu⁴,Hallek Michael¹²,Frenzel Lukas P.¹²,Krause Günter¹²

Affiliation:

1. Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn; Cologne Germany

2. Cluster of Excellence Cellular Stress Responses in Aging-Associated Diseases University of Cologne; Cologne Germany

3. Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich; Switzerland

4. Bayer HealthCare Pharmaceuticals, Global Drug Discovery, TRG Oncology; Berlin Germany

Funder

Deutsche José Carreras Leukämie-Stiftung

German Cancer Aid

Deutsche Forschungsgemeinschaft

German Cancer Aid, Biobank of the Center of Integrated Oncology Cologne Bonn

Bayer, Roche and CLL Global Research Foundation.

Publisher